[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-364571-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-364571-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-term-outcomes-and-survival-rates-of-renal-cell-carcinoma-patients-in-erbil-iraq-a-follow-up-study","Long-term outcomes and survival rates of renal cell carcinoma patients in Erbil, Iraq - a follow-up study","","Renal cell carcinoma (RCC) is a heterogeneous cancer type accounting for 2–4% of global cancer cases, with incidence and outcomes varying across countries; about 4% of cases have a hereditary basis. This retrospective study in Erbil, Iraq analyzes RCC survival rates and factors using 93 patients treated at Nanakaly Hospital and Rizgary Oncology Center from January 2017 to December 2020.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-term-outcomes-and-survival-rates-of-renal-cell-carcinoma-patients-in-erbil-iraq-a-follow-up-study/364571/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-term-outcomes-and-survival-rates-of-renal-cell-carcinoma-patients-in-erbil-iraq-a-follow-up-study/364571.png","ImageObject",300,407,{"name":42,"@type":43},"Ezra","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main aim of the study in Erbil, Iraq?","Question",{"text":63,"@type":64},"To investigate long-term RCC survival rates and identify influential clinical and treatment factors among patients treated at Nanakaly Hospital and Rizgary Oncology Center.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which time period and patient count were included?",{"text":68,"@type":64},"The study used a retrospective cohort spanning January 2017 to December 2020 and included 93 patients.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were significantly associated with survival outcomes?",{"text":72,"@type":64},"TNM stage showed a significant association with survival status, and treatment types including radical nephrectomy and systemic treatments were linked to survival. Recurrence was also significantly associated with mortality.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},364571,1790254745,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":111,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":33,"preview_urls":144},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Salih etal. BMC Cancer (2025) 25:384 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-13040-9](https://doi.org/10.1186/s12885-024-13040-9)  \nRESEARCH Open Access  \nLong-term outcomes and survival rates of renal cell carcinoma patients in Erbil, Iraq:  \na follow-up study  \nFahmi Mohammed Salih 1, Sami Saleem Omar 1,2,3, HawroTaha Hamza4, Karez Sarbast Namiq4, Hana Rizgar Mohammed Ameen 1, Kakil Ibrahim Rasul5 and Sherzad Ali Ismael 6*  \nAbstract  \nBackground Renal cell carcinoma (RCC) is a heterogeneous group of cancers originating from renal tubular and epithelial cells, constituting 2–4% of global cancer cases. Incidence patterns vary internationally, with the Czech Republic and European Baltic countries experiencing higher rates. Despite the majority of cases being sporadic, approximately 4% have a hereditary basis.  \nMethods This study, conducted in Erbil, Iraq, investigates RCC survival rates and influential factors at Nanakaly Hospital and Rizgary Oncology Center. A retrospective analysis spanning January 2017 to December 2020, covering 93 patients, explores demographic, clinical, and treatment variables.  \nResults Out of a total of 93 cases, there were 68 deaths, and 25 cases were censored. This means that 73. 12% of the cases resulted in death, and 26. 88% of the cases were censored. The Kaplan-Meier survival analysis indicates a mean survival time of approximately 5.517 years. Clinical characteristics such as tumor side and histology show no significant associations with survival status, except for theTNM stage (p-value \u003C 0. 001) . While smoking, alcohol history, history of malignancy, and comorbidities demonstrate no significant impact on survival, the study identifies a potential trend associating comorbidities with poorer outcomes (p-value = 0 . 051) . Significant associations emerge with treatment types; radical nephrectomy (p-value = 0 . 004) and systemic treatments (p-value \u003C 0. 001) influence survival. Strikingly, recurrence was significantly associated with mortality (p-value \u003C 0. 001) .  \nConclusions The study reveals a higher RCC had a shorter survival in Erbil compared to international survival. This is attributed to delayed referral s and advanced disease stages. Additionally, the absence of crucial antineoplastic agents negatively affects outcomes. Comorbidities are also found to significantly reduce survival rates. These findings underscore the necessity for an enhanced referral system, improved access to oncological services, and the approval of essential therapies in Erbil.  \nKeywords Renal cell carcinoma, Survival analysis, Nanakali hospital, Rzgary oncology center, Erbil Iraq  \n*Correspondence:  \nSherzad Ali Ismael  \n[sherzad.aismael@gmail.com](sherzad.aismael@gmail.com)  \n1Medical Oncologist, Rizgary Oncology Center, Erbil, KRG, Iraq 2Faculty of Medicine, Koya University, Koya, Erbil, Kurdistan, Iraq 3Kscien Organization, Hamdi Street, Sulaimani, Kurdistan, Iraq  \n4Medical Oncologist, Nanakali Hospital for Blood Diseases & Cancer, Erbil, KRG, Iraq  \n5Department of Medical Oncology, Hamad Medical Corporation, National Center Cancer Care and Research, Doha, Qatar  \n6Community Medicine and Public Health, Head of Faculty of Public Health, Kurdistan Board of Medical Specialties, Erbil, KRG, Iraq  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material.","cbCailzb7lMO6Gb7","https://ap.wps.com/l/cbCailzb7lMO6Gb7","pdf",984818,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"What was the main aim of the study in Erbil, Iraq?\",\"answer\":\"To investigate long-term RCC survival rates and identify influential clinical and treatment factors among patients treated at Nanakaly Hospital and Rizgary Oncology Center.\"},{\"question\":\"Which time period and patient count were included?\",\"answer\":\"The study used a retrospective cohort spanning January 2017 to December 2020 and included 93 patients.\"},{\"question\":\"What factors were significantly associated with survival outcomes?\",\"answer\":\"TNM stage showed a significant association with survival status, and treatment types including radical nephrectomy and systemic treatments were linked to survival. Recurrence was also significantly associated with mortality.\"}]","Long-term outcomes and survival rates of renal cell carcinoma patients in Erbil, Iraq - a follow-up study | PDF",1790158241,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d11aac377e936f106d004e9806d24f94.webp",983,1310,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/97622784f095eb5c4c451fb5c7513202.webp",982,1309,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2402a344dd7a599756df1442984b664.webp",981,1308,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/368ad9b2e2519fed17b4fa741bdc8485.webp",980,1306]